CellSource
VC Fund
Tokyo, Japan
CellSource is a VC fund in Tokyo focused on Consulting and Health Care. CellSource provides adipose-derived stem cell processing services, blood-derived processing contract services, and support services for compliance with laws and regulations in areas such as regenerative medicine.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries CellSource invests in
Stages CellSource invests in
Countries CellSource invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Round size
- Venture - Series Unknown
- $2.3M–$15M
Investment Focus
Industry
- Consulting 2 (67%)
- Health Care 2 (67%)
- Medical 1 (33%)
- Fertility 1 (33%)
- Advertising 1 (33%)
Stage
- Venture - Series Unknown 2 (67%)
- Pre-Seed 1 (33%)
Country
- Japan 2 (67%)
- Malaysia 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hideo Koyama
Auditor
|
Auditor | Total investments: 0 | Find email | |
|
Hirohiko Hanaki
Director, Chief Compliance Officer (CCO) & Head of Regenerative Medicine Business Division
|
Director, Chief Compliance Officer (CCO) & Head of Regenerative Medicine Business Division | Total investments: 0 | Find email | |
|
Kaneshima Hideto
Chief Technical Advisor & Doctor of Medicine
|
Chief Technical Advisor & Doctor of Medicine | Total investments: 0 | Find email | |
Kenta Fujita
Executive Officer
|
Executive Officer | Total investments: 0 | Find email | |
Masahiro Samejima
General Counsel and Patent Attorney
|
General Counsel and Patent Attorney | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tailor App is a digital and live marketing agency. | $2.3M / Venture - Series Unknown / Aug 01, 2024 | ||
| Established in September 2020, Lumirous is a one-stop fertility and reproductive health platform. This platform is created with the sole purpose of supporting those who are facing and looking for a solution to their fertility and reproductive health issues, as well as raising the public's awareness about fertility and reproductive well-being.We are devoting ourselves to building a solid support system for everyone when they are facing fertility and reproductive health issues. | Pre-Seed / Feb 24, 2022 | ||
| CUORiPS is a company developing new medical care based on world's cutting-edge technology originated in Japan. | $14.7M / Venture - Series Unknown / Mar 16, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CellSource invest in?
CellSource invests primarily in Consulting, Health Care and Medical startups, most often at Venture - Series Unknown and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CellSource invest in?
CellSource typically joins rounds of $2.3M–$15M at Venture - Series Unknown. These are whole funding-round sizes, not CellSource's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CellSource took part in.
How do I contact CellSource?
Public channels for CellSource include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CellSource?
The team at CellSource includes Hideo Koyama (Auditor), Hirohiko Hanaki (Director, Chief Compliance Officer (CCO) & Head of Regenerative Medicine Business Division) and Kaneshima Hideto (Chief Technical Advisor & Doctor of Medicine), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
